Sowell Financial Services LLC Salarius Pharmaceuticals, Inc. Transaction History

Sowell Financial Services LLC

  • $2.1 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 07, 2021
SELL
$1.0 - $3.0 $8,597 - $25,791
-8,597 Closed
0 $0
Q4 2020

Jan 13, 2021
BUY
$0.65 - $1.34 $5,588 - $11,519
8,597 New
8,597 $8,000

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $3.08M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Sowell Financial Services LLC Portfolio

Follow Sowell Financial Services LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sowell Financial Services LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sowell Financial Services LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email